2025
SJR Q2
JCR Q2 · 2,9
95 matched articles
SCIE
Journal detail
Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers
- Country
- United Arab Emirates · Middle East
- Type
- journal
- ISSN
-
1389201018734316
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,612
- Quartile Q2
- H-Index 106
- Cites/doc 3,83
- Docs (3y) 448
- Cites (3y) 1.670
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 2,9
- 5Y JIF 2,7
- JCI 0,44
WoS indexes
- SCIE
Subject classification
Categories (SJR)
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,612 | 2,9 | 2,7 | 0,44 | Q3 | 106 |
| 2024 | Q2 | Q3 | 0,493 | 2,6 | 2,4 | 0,46 | Q3 | 101 |
| 2023 | Q2 | Q3 | 0,492 | 2,2 | 2,4 | 0,51 | Q3 | 101 |
| 2022 | Q2 | Q3 | 0,459 | 2,8 | 2,8 | 0,51 | Q3 | 101 |
| 2021 | Q2 | Q3 | 0,547 | 2,8 | 2,8 | 0,48 | Q3 | 101 |
| 2020 | Q2 | Q3 | 0,555 | 2,8 | 2,6 | 0,43 | Q3 | 101 |
| 2019 | Q2 | Q3 | 0,497 | 2,1 | 2,1 | 0,47 | Q3 | 101 |
| 2018 | — | Q4 | — | 1,5 | 1,7 | 0,49 | Q3 | — |
| 2017 | Q2 | Q3 | 0,574 | 1,8 | 2,1 | 0,67 | Q3 | 101 |
| 2016 | Q2 | Q2 | 0,636 | 2,5 | 2,3 | — | — | 101 |
| 2015 | Q1 | Q3 | 0,783 | 1,8 | 2,3 | — | — | 101 |
| 2014 | Q1 | Q3 | 1,005 | 1,9 | 2,6 | — | — | 101 |
| 2013 | Q1 | Q2 | 1,011 | 2,5 | 2,8 | — | — | 101 |
| 2012 | Q1 | Q2 | 1,008 | 2,7 | 3,1 | — | — | 101 |
| 2011 | Q1 | Q2 | 1,16 | 2,8 | 3 | — | — | 101 |
| 2010 | Q1 | Q1 | 1,298 | 3,5 | 3,1 | — | — | 101 |
| 2009 | — | Q1 | — | 3,4 | 3 | — | — | — |
| 2008 | — | Q2 | — | 2,6 | — | — | — | — |
| 2007 | — | Q2 | — | 2,3 | — | — | — | — |
| 2006 | — | Q2 | — | 2,8 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q4 | 207/328 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 173/356 |
| 2024 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q4 | 207/320 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 177/352 |
| 2023 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | Q3 | 237/313 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 204/354 |
| 2022 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q3 | 206/285 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 171/278 |
| 2021 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | Q3 | 227/297 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 188/279 |
| 2020 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q4 | 206/295 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 174/276 |
| 2019 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q3 | 218/297 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 189/271 |
| 2018 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | Q3 | 259/299 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 219/267 |
| 2017 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | Q3 | 226/293 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 192/261 |
| 2016 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 165/290 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 126/257 |
| 2015 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | — | 218/289 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 166/255 |
| 2014 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 213/290 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 152/255 |
| 2013 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 171/291 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 112/256 |
| 2012 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 157/290 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 97/261 |
| 2011 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 151/290 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 93/261 |
| 2010 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 110/286 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 63/252 |
| 2009 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 97/283 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 59/237 |
| 2008 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 133/275 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 82/219 |
| 2007 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 147/263 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 93/205 |
| 2006 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 116/262 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 62/199 |